Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

Autor: Hans Salwender, Uta Bertsch, Katja Weisel, Jan Duerig, Christina Kunz, Axel Benner, Igor W. Blau, Marc Steffen Raab, Jens Hillengass, Dirk Hose, Stefanie Huhn, Michael Hundemer, Mindaugas Andrulis, Anna Jauch, Andrea Seidel-Glaetzer, Hans-Walter Lindemann, Manfred Hensel, Stefan Fronhoffs, Uwe Martens, Timon Hansen, Mohammed Wattad, Ullrich Graeven, Markus Munder, Roland Fenk, Mathias Haenel, Christof Scheid, Hartmut Goldschmidt

Publikováno v: BMC Cancer, Vol 19, Iss 1, Pp 1-11 (2019)

Abstract Background Despite major advances in therapy, multiple myeloma is still an incurable malignancy in the majority of patients. To increase survival, deeper remissions (i.e. CR) translating into longer PFS need to be achieved. Incorporation of

Externí odkaz: https://doaj.org/article/5f886bfc9cbd44f2ba2caaa95f24d69d

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial.

Autor: Mai EK; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany., Bertsch U; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.; National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany., Pozek E; Division of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany., Fenk R; Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany., Besemer B; Department of Internal Medicine II, University Hospital Tübingen, Tübingen, Germany., Hanoun C; Department for Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany., Schroers R; Medical Clinic II-Hematology and Oncology, Ruhr-University Bochum, Bochum, Germany., von Metzler I; Department of Medicine II-Hematology and Oncology, Goethe-University Frankfurt, University Hospital, Frankfurt am Main, Germany., Hänel M; Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany., Mann C; Department for Hematology, Oncology and Immunology, University Hospital Gießen and Marburg, Marburg, Germany., Leypoldt LB; Department of Oncology, Hematology and BMT, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Heilmeier B; Clinic for Oncology and Hematology, Hospital Barmherzige Brueder Regensburg, Regensburg, Germany., Huhn S; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany., Vogel SK; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany., Hundemer M; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany., Scheid C; Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany., Blau IW; Medical Clinic, Charité University Medicine Berlin, Berlin, Germany., Luntz S; Coordination Centre for Clinical Trials (KKS) Heidelberg, Heidelberg, Germany., Weinhold N; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany., Tichy D; Division of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany., Holderried TAW; Department of Hematology, Oncology, Stem Cell Transplantation, Immune and Cell Therapy, Clinical Immunology and Rheumatology, University Hospital Bonn, Bonn, Germany., Trautmann-Grill K; Department of Internal Medicine I, University Hospital Dresden, TU Dresden, Germany., Gezer D; Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany., Klaiber-Hakimi M; Clinic for Hematology, Oncology and Palliative Care, Marien Hospital Düsseldorf, Düsseldorf, Germany., Müller M; Clinic for Hematology, Oncology and Immunology, Klinikum Siloah Hannover, Hannover, Germany., Shumilov E; Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany., Knauf W; Center for Hematology and Oncology Bethanien, Frankfurt am Main, Germany., Michel CS; Department of Internal Medicine III, University Hospital Mainz, Mainz, Germany., Geer T; Department of Internal Medicine III, Diakoneo Clinic Schwäbisch-Hall, Schwäbisch-Hall, Germany., Riesenberg H; Hematology/Oncology Center, Bielefeld, Germany., Lutz C; Hematology/Oncology Center, Koblenz, Germany., Raab MS; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany., Benner A; Division of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany., Hoffmann M; Medical Clinic A, Clinic Ludwigshafen, Ludwigshafen, Germany., Weisel KC; Department of Oncology, Hematology and BMT, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Salwender HJ; Asklepios Tumorzentrum Hamburg, AK Altona and AK St Georg, Hamburg, Germany., Goldschmidt H; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.; National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Dec 09, pp. JCO2402266. Date of Electronic Publication: 2024 Dec 09.

Additional file 2: of Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma

Autor: Marc-Andrea Baertsch, Schlenzka, Jana, Mai, Elias, Merz, Maximilian, Hillengaß, Jens, Raab, Marc, Hose, Dirk, Wuchter, Patrick, Ho, Anthony, Jauch, Anna, Hielscher, Thomas, Kunz, Christina, Luntz, Steffen, Klein, Stefan, Schmidt-Wolf, Ingo, Goerner, Martin, Schmidt-Hieber, Martin, Reimer, Peter, Graeven, Ullrich, Fenk, Roland, Salwender, Hans, Scheid, Christof, Nogai, Axel, Haenel, Mathias, Lindemann, Hans, Martin, Hans, Noppeney, Richard, Weisel, Katja, Goldschmidt, Hartmut

SPIRIT checklist. (DOC 121Â kb)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74a08c4b046cad12a0632772eabd0c15

Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.

Autor: Mai EK; Department of Medicine V, Heidelberg Myeloma Centre, University Hospital Heidelberg, Heidelberg, Germany., Goldschmid H; Department of Medicine V, Heidelberg Myeloma Centre, University Hospital Heidelberg, Heidelberg, Germany; National Centre for Tumour Diseases Heidelberg, Heidelberg, Germany. Electronic address: hartmut.goldschmidt@med.uni-heidelberg.de., Miah K; Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg, Germany., Bertsch U; Department of Medicine V, Heidelberg Myeloma Centre, University Hospital Heidelberg, Heidelberg, Germany; National Centre for Tumour Diseases Heidelberg, Heidelberg, Germany., Besemer B; Department of Internal Medicine II, University Hospital Tübingen, Tübingen, Germany., Hänel M; Department of Internal Medicine III, Clinic Chemnitz, Chemnitz, Germany., Krzykalla J; Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg, Germany., Fenk R; Department of Haematology, Oncology, and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany., Schlenzka J; Department of Medicine V, Heidelberg Myeloma Centre, University Hospital Heidelberg, Heidelberg, Germany., Munder M; Department of Internal Medicine III, University Hospital Mainz, Mainz, Germany., Dürig J; Department for Haematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany., Blau IW; Medical Clinic, Charité University Medicine Berlin, Berlin, Germany., Huhn S; Department of Medicine V, Heidelberg Myeloma Centre, University Hospital Heidelberg, Heidelberg, Germany., Hose D; Department of Medicine V, Heidelberg Myeloma Centre, University Hospital Heidelberg, Heidelberg, Germany., Jauch A; Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany., Kunz C; Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg, Germany., Mann C; Department of Haematology, Oncology and Immunology, Philipps-University Marburg, Marburg, Germany., Weinhold N; Department of Medicine V, Heidelberg Myeloma Centre, University Hospital Heidelberg, Heidelberg, Germany., Scheid C; Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany., Schroers R; Medical Clinic, University Hospital Bochum, Bochum, Germany., von Metzler I; Department of Internal Medicine II, University Hospital Frankfurt, Frankfurt, Germany., Schieferdecker A; Department of Oncology, Haematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany., Thomalla J; Haematology-Oncology Centre, Koblenz, Germany., Reimer P; Clinic for Haematology, Oncology and Stem Cell Transplantation, Evangelische Kliniken Essen-Mitte, Essen, Germany., Mahlberg R; Internal Medicine I, Hospital Mutterhaus der Borromäerinnen, Trier, Germany., Graeven U; Medical Clinic I, Hospital Maria Hilf, Mönchengladbach, Germany., Kremers S; Haematology-Oncology Centre, Lebach, Germany., Martens UM; Haematology, Oncology, Palliative Care, SLK Clinic Heilbronn, Heilbronn, Germany., Kunz C; Haematology and Oncology, Westpfalz-Klinikum, Kaiserslautern, Germany., Hensel M; Mannheimer Onkologie Praxis, Mannheim, Germany., Benner A; Division of Biostatistics, German Cancer Research Center Heidelberg, Heidelberg, Germany., Seidel-Glätzer A; Coordination Centre for Clinical Trials Heidelberg, Heidelberg, Germany., Weisel KC; Department of Oncology, Haematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany., Raab MS; Department of Medicine V, Heidelberg Myeloma Centre, University Hospital Heidelberg, Heidelberg, Germany., Salwender HJ; Asklepios Tumorzentrum Hamburg, Asklepios Hospital Hamburg Altona and St Georg, Hamburg, Germany.

Publikováno v: The Lancet. Haematology [Lancet Haematol] 2024 Feb; Vol. 11 (2), pp. e101-e113.